搜索范围
Y0000458
应用筛选条件
关键词:'Y0000458'
显示 1-30 #N/A 46 条结果 关于 "Y0000458" 范围 论文
Vibeke Hatorp
Clinical pharmacokinetics, 41(7), 471-483 (2002-06-27)
Repaglinide is a novel, fast-acting prandial oral hypoglycaemic agent developed for the treatment of patients with type 2 diabetes whose disease cannot be controlled by diet and exercise alone. Although repaglinide binds to the sulphonylurea binding sites on pancreatic beta-cells
Combination therapy in type 2 diabetes: the role of repaglinide.
R Moses
The Journal of the Association of Physicians of India, 49 Spec No, 62-68 (2001-03-10)
D R Owens et al.
Diabetes, nutrition & metabolism, 15(6 Suppl), 19-27 (2003-04-19)
The major contributory factor to increasing hyperglycaemia in established Type 2 diabetes mellitus (T2DM) appears to be the progressive delay and attenuation of the prandial insulin response. An important consequence of this derangement is that hepatic glucose production is no
Rania N El-Shaheny
Journal of fluorescence, 22(6), 1587-1594 (2012-07-04)
A simple and highly sensitive spectrofluorimetric method was developed and validated for determination of the antidiabetic agent repaglinide (RG) in tablets. The proposed method is based on measurement of the native fluorescence of RG in 0.1 M H(2)SO(4)/methanol medium at
Carlos del Pozo-Fernández et al.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 32(3), 367-373 (2012-05-18)
In this paper we analyse the discrepancies that exist in the widespread prescription of metformin in patients with type 2 diabetes and the lack of guidelines concerning its prescription in the different stages of renal failure. This cross-sectional study includes
Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
M Khamaisi
Diabetic medicine : a journal of the British Diabetic Association, 29(9), 1214-1215 (2012-03-15)
Deaths in trials should always be reported.
Jeppe Schroll
BMJ (Clinical research ed.), 347, f4219-f4219 (2013-07-06)
P Raskin
Diabetes, obesity & metabolism, 10(12), 1167-1177 (2008-05-23)
Type 2 diabetes is characterized by decreases in insulin secretion and insulin sensitivity. Several classes of oral antidiabetic medications are currently approved for the treatment of type 2 diabetes. A stepwise treatment approach from monotherapy to combination therapy is traditionally
Feng Jiang et al.
Biomedical and environmental sciences : BES, 25(1), 23-29 (2012-03-20)
To investigate a potential relationship between Solute carrier family 30 (zinc transporter) member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients. A total of 209 diabetic patients without any
Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.
P S Menon
The Journal of the Association of Physicians of India, 49 Spec No, 50-53 (2001-03-10)
Christina Jarnert et al.
Diabetes & vascular disease research, 9(4), 287-295 (2012-03-02)
Microcirculatory and endothelial dysfunction are signs of cardiovascular engagement in patients with type 2 diabetes. This study tested whether glucose normalisation may reverse this. Thirty-nine T2DM patients (age 61±7 years, 58% females) with signs of mild diastolic dysfunction were randomised
Jie Zhu et al.
Pakistan journal of pharmaceutical sciences, 26(3), 577-584 (2013-04-30)
The effect of pitavastatin and SLCO1B1 genetic background on the pharmacokinetic and pharmacodynamic properties of repaglinide was investigated. In this randomized, placebo-controlled, crossover study, twelve healthy Chinese males were administered with pitavastatin 4 mg/d or the placebo for 5 d
M K Rawat et al.
Current drug delivery, 7(1), 44-50 (2010-01-05)
Repaglinide solid lipid nanoparticles (RG-SLN) were fabricated using stearic acid as lipid. Pluronic F68 (PLF68) and soya lecithin were used as a stabilizer. SLNs were prepared by modified solvent injection and ultrasonication methods. SLNs prepared with modified solvent injection method
Qian Xiang et al.
Pharmacology, 89(1-2), 105-110 (2012-03-09)
The aim of this study was to evaluate the pharmacogenetic variability in the disposition of repaglinide in healthy Chinese subjects. A single dose of 2 mg repaglinide was orally administered to 24 healthy Chinese subjects. The serum concentrations of repaglinide
Carolina Säll et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(7), 1279-1289 (2012-03-28)
Repaglinide is presently recommended by the U.S. Food and Drug Administration as a clinical CYP2C8 probe, yet current in vitro and clinical data are inconsistent concerning the role of this enzyme in repaglinide elimination. The aim of the current study
Drug and therapeutics bulletin, 41(7), 52-54 (2003-07-26)
[symbol: see text] Nateglinide (Starlix-Novartis) and [symbol: see text] repaglinide (NovoNorm-Novo Nordisk) are two of a new class of orally active antidiabetic drugs, the meglitinides. They have a rapid-onset and short-lasting stimulating effect on insulin secretion. Both are licensed for
Toshiyuki Kudo et al.
Drug metabolism and disposition: the biological fate of chemicals, 41(2), 362-371 (2012-11-10)
The plasma concentration of repaglinide is reported to increase greatly when given after repeated oral administration of itraconazole and gemfibrozil. The present study analyzed this interaction based on a physiologically based pharmacokinetic (PBPK) model incorporating inhibition of the hepatic uptake
Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
Hisayuki Katsuyama et al.
Diabetes care, 36(3), e36-e36 (2013-02-23)
J Honkalammi et al.
Clinical pharmacology and therapeutics, 91(5), 846-855 (2012-04-05)
Therapeutic doses of gemfibrozil cause mechanism-based inactivation of CYP2C8 via formation of gemfibrozil 1-O-β-glucuronide. We investigated the extent of CYP2C8 inactivation caused by three different doses of gemfibrozil twice dailyfor 5 days, using repaglinide as a probe drug, in 10
Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
Marc Mennecart et al.
Journal of the American Geriatrics Society, 62(12), 2460-2462 (2014-12-18)
Timothy Bailey
The American journal of medicine, 126(9 Suppl 1), S10-S20 (2013-08-24)
Treating patients with diabetes is one of the most challenging and important activities a physician (primary care physician or specialist) can undertake. A key to successful therapy for type 2 diabetes is the insight that this condition is progressive and
Lesley J Scott
Drugs, 72(2), 249-272 (2012-01-25)
Oral repaglinide (GlucoNorm®; NovoNorm®; Prandin®; Surepost®) is a rapid-acting insulin secretagogue that lowers postprandial glucose (PPG) excursions by targeting early-phase insulin release, with reductions in PPG considered to be important in reducing long-term cardiovascular complications of diabetes mellitus. Repaglinide, a
G E Rutten
Nederlands tijdschrift voor geneeskunde, 145(32), 1547-1550 (2001-08-30)
In about 25% of type 2 diabetes patients, good diabetes control is not attainable with oral blood-glucose lowering drugs. Furthermore, in many people with diabetes the disease deteriorates, despite the use of blood-glucose lowering medication, due to the decline of
Andreas Holstein et al.
Expert opinion on drug metabolism & toxicology, 8(12), 1549-1563 (2012-11-17)
The cytochrome P4502C enzymes account for the metabolism of approximately 20% of therapeutic drugs including certain oral antidiabetic drugs (OADs). This review focuses on the effect of CYP2C enzymes on metabolism of sulphonylureas (SUs), meglitinides, and thiazolidinediones (TZDs) discussing their
R Moses
Expert opinion on pharmacotherapy, 1(7), 1455-1467 (2001-03-16)
Repaglinide is a novel insulin secretagogue that was developed as a prandial glucose regulator for the treatment of people with Type 2 diabetes mellitus. It is used flexibly, taken prior to meals, in order to limit subsequent postprandial blood glucose
Laxmikant Ramvallabh Zawar et al.
Chemical & pharmaceutical bulletin, 60(4), 482-487 (2012-04-03)
The influence of microwave technology on the in vitro dissolution rate and in vivo antihyperglycemic activity of a poorly water soluble drug, repaglinide (RG) was studied. Solid dispersions were prepared by conventional fusion method and microwave method using poloxamer 188.
C R Culy et al.
Drugs, 61(11), 1625-1660 (2001-10-02)
Repaglinide, a carbamoylmethyl benzoic acid derivative, is the first of a new class of oral antidiabetic agents designed to normalise postprandial glucose excursions in patients with type 2 diabetes mellitus. Like the sulphonylureas, repaglinide reduces blood glucose by stimulating insulin
Katsutoshi Mizuno et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(50), 20497-20502 (2012-11-22)
Sperm chemotaxis occurs widely in animals and plants and plays an important role in the success of fertilization. Several studies have recently demonstrated that Ca(2+) influx through specific Ca(2+) channels is a prerequisite for sperm chemotactic movement. However, the regulator
Shan Wang et al.
Die Pharmazie, 67(1), 74-79 (2012-03-08)
The aim of the present study was to evaluate the impact of the UCP2-866 G/A polymorphism on the efficacy of repaglinide in treating patients with diabetes mellitus type 2 (T2DM). 370 patients with T2DM and 166 healthy volunteers were enrolled
Karelle Ménochet et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(9), 1744-1756 (2012-06-06)
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation. The uptake kinetics of seven organic anion-transporting polypeptide substrates was investigated over a concentration range in plated cryopreserved
1/2